Leon-nanodrugs Secures Series D Financing for Nanoencapsulation Production Systems

Munich, August 6, 2024 – leon-nanodrugs GmbH (LEON) announced its successful closing of a Series D financing round. Led by LBBW Venture Capital, the round included new investors and existing shareholders such as Albany Private Equity Holdings Pty Ltd., CD-Venture GmbH, and others. The funds will be used to enhance LEON's portfolio of nanoencapsulation systems for the Cell & Gene Therapy industry.

Christian Nafe, Managing Director & CFO of LEON, highlighted the economic GMP manufacturing of small and individualized batches of nanoencapsulated therapies as a key benefit. Notably, LEON offers systems like NANOscreen, NANOlab®, NANOme®, and NANOus®, all incorporating the advanced FR-JET® reactor technology.

Dr. Frank Mühlenbeck from LBBW Venture Capital joins LEON's Supervisory Board, emphasizing the company's focus on decentralized patient-specific treatments and support for CDMOs. Dr. Hubert Birner of TVM Life Science Management sees this investment as pivotal for LEON, highlighting the growing need for efficient manufacturing solutions in the rise of Cell & Gene Therapies.